BPC-157 is one of the most frequently discussed peptides in laboratory research. It is also one of the most misunderstood. This overview covers what BPC-157 is, where it came from, and what the published scientific literature has actually examined. The aim is to give researchers a clear, citation-backed starting point.
What is BPC-157?
BPC-157 (also written BPC 157) is a synthetic pentadecapeptide, meaning a chain of 15 amino acids. “BPC” stands for “Body Protection Compound.” The sequence is derived from a protein fragment originally identified in gastric juice, which is why much of the literature calls it a “stable gastric pentadecapeptide.”
Its amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Researchers often point to its reported stability in solution, which is unusual for a peptide of this size and has made it convenient to work with in experimental models.
For research purposes, BPC-157 is typically supplied as a lyophilized (freeze-dried) powder. Purity is commonly verified with high-performance liquid chromatography (HPLC) and identity with mass spectrometry.
Where does the research come from?
Most of the BPC-157 literature comes from a research group at the University of Zagreb, Croatia, led by Predrag Sikirić, which has published on the compound for more than three decades. Other independent groups have contributed too, including laboratories in Taiwan and, more recently, groups examining formulation and delivery questions.
That concentration matters. Independent replication is a cornerstone of good science, and several recent reviews note that broader replication outside the original group would strengthen the evidence base.
What have preclinical studies examined?
The great majority of BPC-157 research is preclinical, meaning it was done in cell cultures (in vitro) or in animal models, mostly rats. Key areas of investigation include:
Gastrointestinal models
Given its gastric origin, early work focused on gastrointestinal tissue in rodent models. Reviews from the Zagreb group summarize decades of rodent studies on gastric and intestinal lesion models, including intestinal anastomosis models (Sikirić et al., Pharmaceuticals, 2025).
Tendon and connective tissue models
One of the most cited independent studies is Chang et al. (2011), published in the Journal of Applied Physiology. Using rat tendon explants and cultured tendon fibroblasts, the authors examined tendon cell outgrowth, cell survival under oxidative stress, and cell migration. They reported effects associated with the FAK–paxillin signaling pathway (Chang et al., J Appl Physiol, 2011).
A 2018 review in Current Pharmaceutical Design compared findings on BPC-157 with research on standard angiogenic growth factors across gastrointestinal, tendon, ligament and bone models in animals (Seiwerth et al., 2018).
Vascular and ischemia-reperfusion models
A growing number of rodent papers look at blood vessel formation (angiogenesis) and ischemia-reperfusion injury models. A 2026 critical review in the International Journal of Molecular Sciences assessed this preclinical body of work. It discussed both the reported findings and the methodological limitations of the studies (Demirtaş et al., 2026).
Proposed mechanisms
Researchers have proposed several mechanisms in experimental models, including:
- Interaction with the nitric oxide (NO) system
- Modulation of growth factor signaling, such as VEGF-related pathways
- Effects on cell migration and adhesion signaling (FAK–paxillin)
These are hypotheses drawn from cell and animal data. No single mechanism has been firmly established.
Formulation and analytical challenges
A 2026 review in Pharmaceutics examined BPC-157 from a biopharmaceutical perspective, covering stability, formulation strategies, and the gap between preclinical findings and translational development (Mateescu et al., 2026). For laboratories, this is a reminder that material quality, purity verification and proper storage directly affect how reproducible results are.
Limitations of the current evidence
A responsible reading of the BPC-157 literature should keep these limitations in mind:
- Mostly preclinical. Most data come from rodent and in vitro models, and those findings do not automatically apply to other systems.
- Concentrated authorship. A large share of publications come from one research group.
- Limited controlled clinical data. BPC-157 is not an approved drug in the US or Canada, and peer-reviewed controlled clinical trials are sparse.
Sourcing BPC-157 for research
For reproducible results, researchers should look for:
- HPLC-verified purity (≥99% is a common benchmark)
- Identity confirmation through mass spectrometry
- Lyophilized format with sealed, labeled vials
- Batch traceability
Core Source Peptides supplies BPC-157 10mg at ≥99% purity (HPLC verified), shipped to the US and Canada. Researchers studying related compounds may also be interested in our BPC-157 + TB-500 research blend.
Key takeaways
- BPC-157 is a stable synthetic 15-amino-acid peptide derived from a gastric protein sequence.
- Published research is mainly preclinical, covering gastrointestinal, tendon, vascular and other animal and cell models.
- The proposed mechanisms involve NO signaling, growth factor pathways and cell migration, but none is definitive.
- Independent replication and controlled clinical data are still limited.
References
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. https://pubmed.ncbi.nlm.nih.gov/21030672/
- Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Curr Pharm Des. 2018. https://pubmed.ncbi.nlm.nih.gov/29998800/
- Sikirić P, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key. Pharmaceuticals (Basel). 2025. https://pubmed.ncbi.nlm.nih.gov/40573323/
- Mateescu DM, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Perspectives. Pharmaceutics. 2026. https://pubmed.ncbi.nlm.nih.gov/42198317/
- Demirtaş H, et al. BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence. Int J Mol Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/42794771/
Disclaimer: All products sold by Core Source Peptides are intended strictly for laboratory research use only. They are not for human or veterinary use, are not drugs, foods or cosmetics, and are not intended to diagnose, treat, cure or prevent any disease. This article summarizes published scientific literature for educational purposes only and is not medical advice. Purchasers must be 21+ and qualified to handle research materials.